SEC filings and other documents

CTIM-76 and CT-202 prioritized; $43M cash funds operations into Q4 2027; net loss rises.

Promising T cell engager pipeline targets high unmet needs in solid tumors with strong early data.

CTIM-76 achieved a 29% response rate and low-grade CRS in late-line ovarian cancer patients.

Promising T cell engager pipeline shows early efficacy and safety in solid tumors.

Lead T-cell engager shows early promise in ovarian cancer; key data updates expected soon.

Pipeline advances continue as cash reserves support operations into mid-2027.

Advancing highly selective T cell engagers for solid tumors with key data readouts expected by 2027.

T-cell engager pipeline advances with key data, novel dosing, and combination strategies ahead.

Advancing three T-cell engager programs with key clinical data expected from Q2 2025 onward.

Cash of $66M funds pipeline progress into mid-2027; key clinical data expected in 2026.

T-cell engager programs show early promise, with rapid clinical progress and broad potential.

Promising early clinical results and improved financials position the company for 2026 milestones.

Phase 1 trials advance, cash runway extends to 2027, net loss widens on higher R&D spend.

Phase 1 trials progress, strong cash position, and leadership changes mark Q1 2025.

Cash reserves surged and pipeline advanced, positioning for key clinical milestones in 2025-26.

Pipeline leverages high affinity CD3 T-cell engagers and ADC-validated targets for solid tumors.

Advancing three T-cell engager assets with strong clinical and financial momentum.

Three T-cell engager drugs for solid tumors advance toward phase I, targeting key tumor antigens.

Pipeline expanded, cash strong, and operations funded into 2027 despite higher net loss.

Oncology innovators advance novel therapies with strong investor and regulatory support.